Results 201 to 210 of about 115,048 (305)

B Cell Maturation in Chronic Lymphocytic Leukemia

Immunobiology, 1987
K. Pfeffer, C. Nerl, D. Kabelitz
openaire   +1 more source

First‐Line Treatment of IGHV‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens

European Journal of Haematology, EarlyView.
ABSTRACT Immunoglobulin heavy chain variable region‐unmutated (IGHV‐U) chronic lymphocytic leukemia (CLL) represents a biologically aggressive subgroup with limited responsiveness to chemoimmunotherapy (CIT). To clarify the comparative effectiveness of available frontline options, we conducted a comprehensive Bayesian network meta‐analysis of ...
Santino Caserta, Enrica Antonia Martino, Danilo Lofaro, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Fortunato Morabito, Valter Gattei, Massimo Gentile   +13 more
wiley   +1 more source

Can hyperleukocytosis be caused by a non-hematologic condition? A 10-year retrospective tertiary-care center cohort study. [PDF]

Ann Med
Moutzouri E, Häfliger E, Jalowiec KA, Chanias I, Andres M, Schnegg-Kaufmann A, De Angelis A, Kronig MN, Pabst T, Bacher U, Baran N, Angelillo-Scherrer A, Meyer SC, Daskalakis M, Rovó A.   +14 more
europepmc   +1 more source

Bone Marrow Pathology in Cold Agglutinin‐Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases

European Journal of Haematology, EarlyView.
ABSTRACT Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B‐cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO‐HAEM5 introduced a description of the CAD‐associated lymphoproliferative disorder (CAD‐LPD) in ...
Anne‐Marie L. Becking, Sophie J. Bernelot Moens, Marie José Kersten, Femke V. M. Mulder, Steven T. Pals, Lianne Koens, Josephine M. I. Vos   +6 more
wiley   +1 more source

Should the current diagnostic criteria for CLL be reconsidered? A reply to Johnstone et al. "De-diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria". [PDF]

Hemasphere
Matos DM.
europepmc   +1 more source

Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients

British Journal of Haematology, EarlyView.
Takaaki Ono, Takashi Okada, Ryo Ikeda, Mitsuru Yamashita, Katsumi Koyauchi, Fumisato Takagi, Miwa Adachi, Tomonari Takemura, Kozue Mitsui, Yasuyuki Nagata   +9 more
wiley   +1 more source

Development of Chimeric Antigen Receptor‐Modified NK Cells for the Immunotherapy of Adult T‐Cell Leukemia/Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Adult T‐cell leukemia/lymphoma (ATL) is an aggressive hematological malignancy with a poor prognosis and limited therapeutic options. ATL cells exhibit aberrant surface glycosylation patterns resulting from dysregulated glycosyltransferase expression, representing a potentially tumor‐specific therapeutic target.
Yuichiro Uchida, Seigo Tateo, Masahiro Wakao, Hiroyuki Shinchi, Hayate Sawayama, Akira Fukumoto, Makoto Yoshimitsu, Yasuo Suda   +7 more
wiley   +1 more source

Major histocompatibility complex class II expression on CD14^pos cells in canine peripheral blood across various hematologic disorders-a preliminary study. [PDF]

J Vet Diagn Invest
Martínez-Caro J, Agulla B, Lemos M, Pastor J.   +3 more
europepmc   +1 more source

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2 [PDF]

, 2018
Bartlett, Nancy L, et al.,
core   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, EarlyView.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source